Dihexa, Telmisartan (Candesartan, Losartan), PEPITEM, Cognitive Enhancement and the example of Pitt-Hopkins

 

A reader recently left an interesting comment on my earlier post about telmisartan. They wrote that they had been using Dihexa for a couple of months and had noticed new vocalizations and unexpected progress with toilet training in their child. They also mentioned another peptide, PEPITEM, which they had come across while reading about bone metabolism and inflammation.

This comment prompted me to look more closely at how several topics might intersect biologically: Dihexa, angiotensin receptor blockers such as telmisartan, the peptide PEPITEM, and conditions like Pitt-Hopkins syndrome.

 

What is a peptide?

Peptides are short chains of amino acids, the same building blocks that make up proteins. They act as signaling molecules in the body and regulate many biological processes. Examples of natural peptide hormones include insulin and oxytocin.

Scientists often design synthetic peptides to mimic or modify these natural signals. Some peptides have become successful medicines. A well-known example is semaglutide, used to treat diabetes and obesity.

In recent years peptides have become very popular in longevity and biohacking circles. This is partly because modern biology has discovered many new peptide signaling systems. These regulate metabolism, immune responses, tissue repair, and brain plasticity.

Another reason is that peptide manufacturing has become much cheaper. Automated peptide synthesis now allows laboratories to produce peptides easily. As a result, some research peptides are now sold online.

Many of these compounds are marketed as “research chemicals”. Examples often discussed online include BPC-157 and Dihexa. These compounds originated in laboratory research.

However, most of them have not gone through proper human clinical trials. Their long-term safety and effectiveness are therefore unknown.

Social media and podcasts have amplified interest in these substances. This has created a large grey market for experimental peptide therapies.

Scientists remain cautious because peptides can have strong biological effects. Problems can include uncertain purity, incorrect dosing, and lack of safety data.

Despite these concerns, peptides remain an important area of medical research. Many future medicines are likely to be peptide-based.

The reason is simple, biology uses peptides as a major language of cellular communication. They control processes ranging from metabolism to immune function and brain signaling.

This is why peptides sometimes appear in discussions of neurological conditions.

Many pathways involved in brain development and synaptic plasticity are regulated by peptide signals.

  

Dihexa and the angiotensin system

Dihexa was originally developed from angiotensin IV, a fragment of angiotensin II that belongs to the renin–angiotensin system. While this system is best known for regulating blood pressure, it also has important roles in the brain.

In the 1990s researchers noticed that angiotensin IV could improve learning and memory in animal experiments. This led scientists to design molecules that could mimic these effects but cross the blood–brain barrier and remain stable in the body. One of these molecules was Dihexa.

Interestingly, Dihexa does not appear to work primarily through classical angiotensin receptors. Instead it activates the HGF/MET pathway, which regulates neuronal growth, dendritic branching and synapse formation. In laboratory experiments Dihexa has shown very strong synaptogenic effects, meaning it can promote the formation of new synaptic connections between neurons.

This is why it sometimes appears in discussions of cognitive enhancement or experimental neurological treatments. However, it is important to stress that Dihexa has never undergone proper human clinical trials, so its safety profile and long-term effects remain unknown. It is somewhat surprising that it is sold online as a “supplement” or research compound, since it is really a laboratory-designed molecule rather than a traditional dietary supplement.

 

BDNF and synaptic plasticity

Some autism clinicians have experimented with approaches intended to increase brain levels of BDNF (brain-derived neurotrophic factor), a key regulator of synaptic plasticity and neuronal survival.

BDNF promotes dendritic growth, synapse formation and learning-related plasticity. In many ways it is one of the brain’s central “growth signals”. Dihexa became famous in neuroscience circles partly because some laboratory studies suggested it could stimulate synapse formation even more strongly than BDNF, although those findings were mainly from cell culture experiments.

The two pathways are different but converge on similar intracellular signaling networks that regulate synaptic growth.

Interestingly, one of the most reliable ways to increase BDNF is not a drug at all but physical exercise. Exercise stimulates BDNF production in the hippocampus through a combination of increased neuronal activity, metabolic signaling and muscle-derived molecules such as irisin. High-impact activity may also stimulate endocrine signals from bone, including osteocalcin, which can influence brain function.

 

Angiotensin receptor blockers and the brain

The drugs discussed in some of my previous articles—telmisartan, candesartan and losartan—belong to the class of angiotensin receptor blockers (ARBs). They block the AT1 receptor, which is activated by angiotensin II.

Although these drugs are prescribed for hypertension, the brain has its own local renin–angiotensin system. In the central nervous system angiotensin signaling influences neuroinflammation, oxidative stress, cerebral blood flow and neuronal excitability.

Blocking the AT1 receptor tends to reduce inflammatory signaling and shift the balance toward protective pathways.

Telmisartan is particularly interesting because it also activates the nuclear receptor PPAR-gamma, which influences mitochondrial function, metabolic signaling and inflammation in neurons.

Candesartan is often considered one of the more brain-penetrant ARBs and has shown neuroprotective effects in some experimental models.

Losartan has attracted attention because it can reduce excessive TGF-beta signaling, a pathway involved in inflammation and tissue remodeling.

Telmisartan might theoretically be more relevant in autism where metabolic stress and inflammation dominate (because of PPAR-γ activation). Losartan might be more relevant where excessive tissue-remodeling or TGF-β signaling plays a role. In the brain, tissue remodeling involves:

• synapse formation and elimination
• growth of dendrites and axons
• restructuring of the extracellular matrix around neurons
• activation of glial cells

Losartan is used to treat Marfan syndrome. Marfan syndrome is a systemic connective-tissue disorder that affects many parts of the body, particularly the heart.

Some studies have reported altered TGF-β signaling in certain forms of autism, suggesting that immune and tissue-remodeling pathways may contribute to aspects of neurodevelopment in at least some individuals. Losartan could theoretically influence these biological processes.

These mechanisms do not directly overlap with Dihexa’s synapse-forming activity, but they may influence the overall biological environment in the brain by reducing inflammatory and metabolic stress.

 

The peptide PEPITEM

The reader also mentioned PEPITEM, short for “PEPtide Inhibitor of Trans-Endothelial Migration”.

PEPITEM regulates the movement of immune cells across blood vessel walls. In simple terms, it helps control whether inflammatory immune cells leave the bloodstream and enter tissues.

This pathway has been studied mainly in inflammatory diseases. By limiting immune-cell migration, the PEPITEM pathway can reduce tissue inflammation.

Interestingly, the same pathway also influences bone metabolism because immune signaling strongly affects osteoclast activity and bone resorption.

 

Why bone biology keeps appearing

One surprising theme linking these topics is the intersection between inflammation, bone metabolism and the renin–angiotensin system.

Angiotensin II can stimulate osteoclast activity and promote bone resorption. Blocking the AT1 receptor with ARBs may therefore modestly reduce inflammatory bone loss. Some observational studies have suggested that ARB use may be associated with slightly higher bone density or lower fracture risk.

Given how closely immune signaling and bone metabolism interact, it is not surprising that peptides affecting immune-cell trafficking, like PEPITEM, also influence bone remodeling pathways.

 

Pitt-Hopkins syndrome as an example

Pitt-Hopkins syndrome is caused by mutations in the transcription factor TCF4. This gene regulates many downstream processes involved in neuronal development, synaptic maturation and network formation.

In experimental models of Pitt-Hopkins and related neurodevelopmental disorders, researchers often observe abnormalities in synaptic development and neuronal connectivity.

Because of this, some therapeutic ideas have focused on pathways that influence synaptic plasticity, neuronal growth or inflammatory signaling.

The HGF/MET pathway activated by Dihexa is one such pathway. The MET gene has also been linked to autism genetics in several studies, and reduced MET signaling has been associated with altered cortical connectivity.

This does not mean that Dihexa is a treatment for Pitt-Hopkins syndrome or autism, but it is certainly plausible.

We saw in previous posts that autism can be broadly divided in hypo/hyper (too little/much) active pro-growth signaling pathways. Pitt Hopkins would be in the hypo category, so increasing activity should be beneficial.

The unknown issue with Dihexa is that it has not be tested thoroughly in humans, so long term use might not be wise, particularly in older people.

The totally safe way to increase pro-growth signaling is via daily aerobic exercise, which comes up again in the next post, which looks at translating recent Alzheimer's research to autism. 

 

A broader pattern

What the reader’s comment illustrates is something that appears frequently in biomedical research, apparently unrelated compounds often converge on a small number of biological control systems.

In this case we see several different layers of regulation:

– the renin–angiotensin system influencing inflammation and metabolic signaling
– growth factor pathways such as HGF/MET and BDNF regulating synapse formation
– immune trafficking pathways such as PEPITEM controlling inflammatory cell migration
– transcriptional regulators such as TCF4 governing neuronal development

Each operates at a different level, but they all ultimately influence how neurons grow, connect and function.

This does not mean that compounds like Dihexa or peptides such as PEPITEM will become treatments for neurological conditions. Most remain at a very early stage of research.

But it does highlight how discoveries in cardiovascular biology, immunology, bone metabolism and neuroscience increasingly intersect.

 

Conclusion

Dihexa and telmisartan start from the same hormonal system but act very differently:

• Dihexa directly stimulates synapse formation through growth-factor signaling.
• Telmisartan reduces inflammation and metabolic stress that may impair neuronal function.

The overlap lies mainly in their potential downstream effects on neuronal plasticity, not in their primary mechanism of action.

In the case of Pitt Hopkins syndrome both might be potentially beneficial, although through very different mechanisms, but no clinical evidence exists.

Dihexa acts by activating the HGF/MET pathway, which promotes synapse formation, dendritic growth and neuronal plasticity. Since Pitt-Hopkins syndrome involves impaired neuronal network development caused by mutations in the TCF4 transcription factor, pathways that enhance synaptic growth should attract scientific interest.

Telmisartan works in a different way. By blocking the AT1 receptor of the renin–angiotensin system it reduces inflammatory signaling and oxidative stress, and it also activates the nuclear receptor PPAR-γ, which influences mitochondrial metabolism and cellular stress responses. These effects could potentially improve the cellular environment in which neurons function.

In simple terms, Dihexa attempts to directly stimulate synapse formation, whereas telmisartan may reduce biological stresses that interfere with normal neuronal signaling.

Both approaches therefore touch on biological processes that are relevant to brain development and plasticity.

Dihexa is used by some autism clinicians in the US.